Document is current
Any future updates will be listed below
-
Authors
Rodrigues, Manuel https://orcid.org/0000-0002-5443-0802
Ramtohul, Toulsie
Rampanou, Aurore
Sandoval, José Luis
Houy, Alexandre https://orcid.org/0000-0001-6267-2353
Servois, Vincent https://orcid.org/0000-0002-8378-8432
Mailly-Giacchetti, Léah
Pierron, Gaelle https://orcid.org/0000-0002-2536-7680
Vincent-Salomon, Anne https://orcid.org/0000-0001-5754-5771
Cassoux, Nathalie
Mariani, Pascale
Dutriaux, Caroline
Pracht, Marc
Ryckewaert, Thomas
Kurtz, Jean-Emmanuel
Roman-Roman, Sergio
Piperno-Neumann, Sophie
Bidard, François-Clément https://orcid.org/0000-0001-5932-8949
Stern, Marc-Henri https://orcid.org/0000-0002-8100-2272
Renault, Shufang https://orcid.org/0000-0001-9234-1002
- License Information
-
More Information
Article History
Received: 5 March 2024
Accepted: 30 September 2024
First Online: 14 October 2024
Competing interests
: M.R. reports personal fees for serving as an advisor from Merck Sharp & Dohme, AstraZeneca, GlaxoSmithKline, Immunocore; travel support from AstraZeneca; funds to his institution to support research from Merck Sharp & Dohme, Janssen-Cilag, Daiichi-Sankyo. F-C.B. received advisory board fees from Pfizer, AstraZeneca, Daiichi-Sankyo, Lilly, Novartis, Menarini, Caris Life Science, GE Healthcare, Exact Sciences, Gilead, Roche, SAGA Diagnostics; research support from AstraZeneca, Novartis, Pfizer, Prolynx, Merck KGAa, GE Healthcare, SAGA Diagnostics, Personalis; travel support from AstraZeneca, Novartis, Pfizer, Daiichi-Sankyo. A.V-S. received research grant from AstraZeneca, Daiichi-Sankyo, Ibex, Owkin, Primaa; travel support from AstraZeneca, Roche; conference fees from Daiichi-Sankyo, Exactsciences, Amgen; honoraria for conferences or lectures from AstraZeneca, Roche, MSD, Exactsciences; advisory board or consultant fees from Ibex, Primaa. M.P. received advisory board fees and travel support from AstraZeneca. J-E.K. reports personal fees for serving as an advisor from GlaxoSmithKline, Clovis Oncology, Tesaro, AstraZeneca, and Dragonfly Therapeutics; funds to his institution to support research from Merck Sharp & Dohme; travel support from Roche, PharmaMar, Tesaro. S.P-N reports personal fees for serving as an advisor from Immunocore and Pierre Fabre and travel support from Immunocore, Novartis. M-H.S. and S.R. received research support from Immunocore. The remaining authors declare no competing interests.
